- Home
- ACAD vs FHI Comparison
ACAD vs FHI Comparison
Compare ACAD & FHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- FHI
- Stock Information
- Founded
- ACAD 1993
- FHI 1955
- Country
- ACAD United States
- FHI United States
- Employees
- ACAD N/A
- FHI N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- FHI Investment Managers
- Sector
- ACAD Health Care
- FHI Finance
- Exchange
- ACAD Nasdaq
- FHI Nasdaq
- Market Cap
- ACAD 3.8B
- FHI 3.4B
- IPO Year
- ACAD 2004
- FHI N/A
- Fundamental
- Price
- ACAD $20.98
- FHI $46.13
- Analyst Decision
- ACAD Buy
- FHI Hold
- Analyst Count
- ACAD 18
- FHI 7
- Target Price
- ACAD $27.71
- FHI $42.57
- AVG Volume (30 Days)
- ACAD 2.1M
- FHI 686.7K
- Earning Date
- ACAD 08-05-2025
- FHI 07-31-2025
- Dividend Yield
- ACAD N/A
- FHI 2.94%
- EPS Growth
- ACAD N/A
- FHI 2.09
- EPS
- ACAD 1.37
- FHI 3.58
- Revenue
- ACAD $996,283,000.00
- FHI $1,659,262,000.00
- Revenue This Year
- ACAD $13.39
- FHI $5.75
- Revenue Next Year
- ACAD $10.59
- FHI $3.82
- P/E Ratio
- ACAD $15.33
- FHI $12.90
- Revenue Growth
- ACAD 22.42
- FHI 2.19
- 52 Week Low
- ACAD $13.40
- FHI $31.94
- 52 Week High
- ACAD $25.23
- FHI $46.84
- Technical
- Relative Strength Index (RSI)
- ACAD 45.70
- FHI 74.57
- Support Level
- ACAD $20.75
- FHI $45.03
- Resistance Level
- ACAD $23.09
- FHI $46.84
- Average True Range (ATR)
- ACAD 0.78
- FHI 0.70
- MACD
- ACAD -0.20
- FHI 0.18
- Stochastic Oscillator
- ACAD 9.83
- FHI 85.45
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About FHI Federated Hermes Inc.
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $800 billion in managed assets at the end of September 2024, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (3%), and money market (74%) funds. The firm's cash-management operations are expected to generate around 51% of Federated's revenue this year, compared with 29%, 12%, and 7%, respectively, for the equity, fixed-income, and alternatives/multi-asset operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (65% of AUM), institutional investors (26%), and international clients (9%).